Acute Lymphoblastic Leukemia: Nursing Notes on Asparaginase Hypersensitivity and Silent Inactivation
Wednesday, December 01, 2021 at 7:00 pm ET – 8:00 pm ET



This activity is accredited for 1.0 hrs of complimentary CE for nurses

Program Overview
Outcomes in acute lymphoblastic leukemia (ALL) have improved significantly for children over the past decades, due primarily in part to multi-agent chemotherapy. Asparaginases are a cornerstone of treatment for ALL, a critical component of many treatment protocols, and is used for remission induction and intensification treatment. Despite this success, hypersensitivity and silent inactivation remain a significant problem with treatment, so it is critical to rapidly identify when this occurs and know how to manage it. This live webinar will provide an interactive opportunity to test your knowledge and learn how to recognize, manage, and treat these complications.

Target Audience
This educational activity is designed for nurses who provide care for pediatric and young adult patients with acute lymphoblastic leukemia.

Learning Objectives
Upon completion of this educational activity, participants should be able to:

  • Discuss the history of asparaginase in the treatment of pediatric and adolescent and young adult (AYA) patients with ALL
  • Describe the pharmacokinetic properties, routes of administration, and adverse reactions of ASNase and PEG ASNase formulations, including approved and emerging agents
  • Recount the pathophysiology of the hypersensitivity and inactivation process
  • Identify optimal methods of measuring subclinical hypersensitivity or silent inactivation
  • Discuss the treatment of subclinical hypersensitivity or silent inactivation to E. coli-derived asparaginase, including agents recently approved and in late-stage clinical trials
  • Implement optimal approaches for nurse monitoring, hypersensitivity reaction management, and patient/family education for pediatric and AYA patients with ALL and their families

Faculty

Katelyn Oranges, MSN, CRNP, CPHON Joseph Sciasci, PharmD, BCOP
Katelyn Oranges, MSN, CRNP, CPHON
Hematologic Malignancies Nurse Practitioner
The Children’s Hospital of Philadelphia
Philadelphia, Pennsylvania
Joseph Sciasci, PharmD, BCOP
Clinical Pharmacy Specialist
St. Jude Children’s Research Hospital
Memphis, Tennessee

Agenda

10 minutes Overview of Asparaginase Treatment in Pediatric and AYA ALL
20 minutes Asparaginase Hypersensitivity and Silent Inactivation
20 minutes Interactive Case Challenge: Subclinical Hypersensitivity to E.coli-derived Asparaginase
  • Patient and family education
  • Vital signs and observation during administration of E.coli-derived asparaginase
  • Post-administration observation duration
  • Identification of subclinical hypersensitivity or silent inactivation
  • Treatment of hypersensitivity or silent inactivation to E.coli-derived asparaginase
10 minutes Question and Answer Session, Key Points for Practice, and Conclusions

Accreditation

MediCom Worldwide, Inc. Nursing Credit
MediCom Worldwide, Inc. is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 21-038-148

Disclosure
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an accredited continuing education activity to disclose all financial relationships with any ineligible company. The ACCME defines “ineligible companies” as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products by or on patients. A relevant relationship exists if a financial relationship in any amount exists between the person in control of content and an ineligible company; the financial relationship existed during the past 24 months and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. MediCom will identify mitigation strategies for all persons with relevant financial relationships who control content of the educational activity.

Faculty Disclosures
Katelyn Oranges, faculty for this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

Dr. Joseph Sciasci, faculty for this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses of products or devices.

Planning Committee
Joan Meyer, RN, MHA, Executive Director, Isabelle Vacher, Vice President of Educational Strategy, and Andrea Mathis, Project Manager, planners for this educational activity, have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Peer Reviewer
Peer reviewer(s) for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Instructions for Participation and Credit
In order to receive credit, all participants must complete the post-test and activity evaluation following the activity. Partial credit will not be awarded for this activity. Participants must receive a minimum score of 70% on the self-assessment to qualify for CE credit.

Participants will receive a link to complete the post-test and evaluation at the end of the program. Certificates will be emailed within 4 weeks to those who have successfully met the criteria for completion. If you do not click on the link at the end of the program, you will receive an email no later than 48 hours following the meeting with instructions to complete and submit your activity evaluation and post-test.

If you have any questions regarding this activity, please contact MediCom Worldwide, Inc. at 800-408-4242, x110 or cjacobus@medicaled.com.

Provided by
MediCom Worldwide, Inc.

Supported by educational grants from Jazz Pharmaceuticals and Servier Pharmaceuticals LLC.
Acute Lymphoblastic Leukemia: Nursing Notes on Asparaginase Hypersensitivity and Silent Inactivation